Treatment of heart failure with preserved ejection fraction

Pharmacotherapy

Volumn 31, Issue 3, 2011, Pages 312-331

  Barnes, Megan M ^a,b   Dorsch, Michael P ^a,b   Hummel, Scott L ^c   Koelling, Todd M ^c   Bleske, Barry E ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diastolic heart failure; Heart failure; Normal ejection fraction; Preserved ejection fraction

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NEBIVOLOL; PERINDOPRIL; PLACEBO; PROPRANOLOL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

AGE; ANEMIA; BETA ADRENERGIC STIMULATION; BLOOD PRESSURE REGULATION; CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEEDING BEHAVIOR; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE PRESERVED EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPERTENSION; ISCHEMIA; KIDNEY FAILURE; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT ATTITUDE; PREVALENCE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE VOLUME;

EID: 79952474816     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.3.312     Document Type: Review

References (71)

1. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387-93.
2. Wu EB, Yu CM. Management of diastolic heart failure: a practical review of pathophysiology and treatment trial data. Int J Clin Pract 2005;59:1239-46. (Pubitemid 43904533)
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics: 2010 update - a report from the American Heart Association. Circulation 2010;121:e46-215.
4. Thohan V, Patel S. The challenges associated with current clinical trials for diastolic heart failure. Curr Opin Cardiol 2009;24:230-8.
5. Fitzgibbons TP, Meyer TE, Aurigemma GP. Mortality in diastolic heart failure: an update. Cardiol Rev 2009;17:51-5.
6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9. (Pubitemid 44079340)
7. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-55.
8. Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-42. (Pubitemid 37000196)
9. Gustafsson F, Torp-Pedersen C, Brendorp B, et al. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003;24:863-70. (Pubitemid 36528566)
10. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-16. (Pubitemid 44708051)
11. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41:1510-18. (Pubitemid 36543369)
12. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9. (Pubitemid 44088349)
13. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (≥55%) versus those with mildly reduced (40-55%) and moderately to severely reduced (< 40%) fractions. Am J Cardiol 2008;101:1151-6.
14. Lim HS, Beadle R, Frenneaux M. Death and dying in heart failure with normal ejection fraction. Am J Cardiol 2009;104:1311-14.
15. Aurigemma GP, Gaasch WH. Clinical practice: diastolic heart failure. N Engl J Med 2004;351:1097-105.
16. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33.
17. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50. (Pubitemid 47614269)
18. Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:475-539.
19. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
20. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
21. Satpathy C, Mishra TK, Satpathy R, Satpathy HK, Barone E. Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician 2006;73:841-6. (Pubitemid 43340509)
22. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol 2010;55:1701-10.
23. Grewal J, McKelvie R, Lonn E, et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Failure 2008;10:252-9. (Pubitemid 351343862)
24. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide echocardiographic severity of diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601. (Pubitemid 34123434)
25. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004;6:281-7.
26. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991;17:1065-72.
27. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9.
28. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005;112:2254-62. (Pubitemid 41464567)
29. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138-47. (Pubitemid 44747894)
30. Colombo PC, Onat D, Sabbah HN. Acute heart failure as "acute endothelitis": interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008;10:170-5.
31. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 2005;11:177-87. (Pubitemid 40462419)
32. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49:198-207. (Pubitemid 46070209)
33. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119-26.
34. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002;105:1195-201.
35. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005;47:357-66. (Pubitemid 41188342)
36. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure: treatment strategies. Heart Fail Rev 2008;13:367-75.
37. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-50. (Pubitemid 35265382)
38. Phan TT, Nallur Shivu G, Abozguia K, et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:29-34.
39. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the health ABC (health, aging, and body composition) study. J Am Coll Cardiol 2010;55:2129-37.
40. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. (Pubitemid 36068707)
41. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008;118:2259-67.
42. Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999;33:1567-72.
43. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.
44. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45. (Pubitemid 44453578)
45. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-9. (Pubitemid 27329224)
46. Roongsritong C, Sutthiwan P, Bradley J, Simoni J, Power S, Meyerrose GE. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005;28:484-7. (Pubitemid 41434276)
47. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94:573-80. (Pubitemid 351580128)
48. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the National Heart, Lung, and Blood Institute. Circulation 2009;119:3070-7.
49. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-23. (Pubitemid 36092188)
50. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart 2008;94:1450-5.
51. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-85. (Pubitemid 351806482)
52. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-4. (Pubitemid 23065018)
53. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17:133-9. (Pubitemid 37174687)
54. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003;362:777-81. (Pubitemid 37093918)
55. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007;369:2079-87. (Pubitemid 46935945)
56. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-65. (Pubitemid 39031173)
57. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674-82.
58. Nodari S, Metra M, Dei Cas L. β-Blocker treatment of patients with diastolic heart failure and arterial hypertension: a prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 2003;5:621-7. (Pubitemid 38043967)
59. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function: results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-61. (Pubitemid 38746589)
60. Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004;94:448-53. (Pubitemid 39127468)
61. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. β-Blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure). J Am Coll Cardiol 2009;53:2150-8.
62. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-6. (Pubitemid 20360593)
63. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002;56:57-62.
64. Meyer P, White M, Mujib M, et al. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol 2008;102:1681-6.
65. Dickstein K, Cohen-Solal A, Filippatos G, et al, for the Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Developed in collaboration with the Heart Failure Association of the ESC and endorsed by the European Society of Intensive Care Medicine. Eur Heart J 2008;29:2388-442.
66. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-7.
67. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-63. (Pubitemid 41022076)
68. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. II. Causal mechanisms and treatment. Circulation 2002;105:1503-8.
69. Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction Circulation 2008;117:2051-60.
70. Tapp RJ, Sharp A, Stanton AV, et al. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian cardiac outcomes trial) substudy. J Am Coll Cardiol 2010;55:1875-81.
71. Garg R, Gorlin R, Smith T, Yusuf S, for the Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33. (Pubitemid 27085732)